Eric Caudron
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eric Caudron has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Antoine Dowek
Clinical Pharmacy Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France; Université Paris-Saclay, Lipides : systèmes analytiques et biologiques, 91400 Orsay, France
2 shared publications - Frederic Riffard
Département Chimie Sciences des Matériaux
2 shared publications - Henri Buscail
LVEEM, Université Clermont Auvergne, Le Puy en Velay, France
2 shared publications - Marion Berge
Pharmacy Department, Georges Pompidou European Hospital, AP-HP, Paris, France
2 shared publications Patrice Prognon
U-Psud, Univ. Paris-Saclay, Lip(Sys)(2) Chimie Analytique Pharmaceutique, EA7357, UFR-Pharmacy, Châtenay-Malabry, France; European Georges Pompidou Hospital (AP-HP), Pharmacy Department, Paris, France
2 shared publications- Ali Tfayli
Lipides: systèmes analytiques et biologiques, Université Paris-Saclay, Châtenay-Malabry, France
1 shared publication
Latest Publications
- Open Access
- 25 March 2025
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 17 (16) , 3274-3282
Rapid quantification and classification of five vinca alkaloids used in cancer therapy by flow injection analysis with UV detection and chemometrics
UV-visible spectroscopy with chemometrics enables accurate vinca alkaloid discrimination, while Bland–Altman analysis compares HPLC and FIA. Real-world data validate findings, ensuring robust control of anticancer drugs for precise patient dosing.
- 25 March 2025
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 17 (16) , 3274-3282
Open AccessRapid quantification and classification of five vinca alkaloids used in cancer therapy by flow injection analysis with UV detection and chemometrics
UV-visible spectroscopy with chemometrics enables accurate vinca alkaloid discrimination, while Bland–Altman analysis compares HPLC and FIA. Real-world data validate findings, ensuring robust control of anticancer drugs for precise patient dosing.
- Open Access
A Case of Phage Therapy against Pandrug-Resistant Achromobacter xylosoxidans in a 12-Year-Old Lung-Transplanted Cystic Fibrosis Patient
Bacteriophages are a promising therapeutic strategy among cystic fibrosis and lung-transplanted patients, considering the high frequency of colonization/infection caused by pandrug-resistant bacteria. However, little clinical data are available regarding the use of phages for infections with Achromobacter xylosoxidans. A 12-year-old lung-transplanted cystic fibrosis patient received two rounds of phage therapy because of persistent lung infection with pandrug-resistant A. xylosoxidans. Clinical tolerance was perfect, but initial bronchoalveolar lavage (BAL) still grew A. xylosoxidans. The patient’s respiratory condition slowly improved and oxygen therapy was stopped. Low-grade airway colonization by A. xylosoxidans persisted for months before samples turned negative. No re-colonisation occurred more than two years after phage therapy was performed and imipenem treatment was stopped. Whole genome sequencing indicated that the eight A. xylosoxidans isolates, collected during phage therapy, belonged to four delineated strains, whereby one had a stop mutation in a gene for a phage receptor. The dynamics of lung colonisation were documented by means of strain-specific qPCRs on different BALs. We report the first case of phage therapy for A. xylosoxidans lung infection in a lung-transplanted patient. The dynamics of airway colonization was more complex than deduced from bacterial culture, involving phage susceptible as well as phage resistant strains.
Open AccessA Case of Phage Therapy against Pandrug-Resistant Achromobacter xylosoxidans in a 12-Year-Old Lung-Transplanted Cystic Fibrosis Patient
Bacteriophages are a promising therapeutic strategy among cystic fibrosis and lung-transplanted patients, considering the high frequency of colonization/infection caused by pandrug-resistant bacteria. However, little clinical data are available regarding the use of phages for infections with Achromobacter xylosoxidans. A 12-year-old lung-transplanted cystic fibrosis patient received two rounds of phage therapy because of persistent lung infection with pandrug-resistant A. xylosoxidans. Clinical tolerance was perfect, but initial bronchoalveolar lavage (BAL) still grew A. xylosoxidans. The patient’s respiratory condition slowly improved and oxygen therapy was stopped. Low-grade airway colonization by A. xylosoxidans persisted for months before samples turned negative. No re-colonisation occurred more than two years after phage therapy was performed and imipenem treatment was stopped. Whole genome sequencing indicated that the eight A. xylosoxidans isolates, collected during phage therapy, belonged to four delineated strains, whereby one had a stop mutation in a gene for a phage receptor. The dynamics of lung colonisation were documented by means of strain-specific qPCRs on different BALs. We report the first case of phage therapy for A. xylosoxidans lung infection in a lung-transplanted patient. The dynamics of airway colonization was more complex than deduced from bacterial culture, involving phage susceptible as well as phage resistant strains.
- 28 January 2019
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 25 (5) , 1195-1203
Pharmaceutical interventions to improve safety of chemotherapy-treated cancer patients: A cross-sectional study
Purpose: Cancer chemotherapy is a high-risk process. To improve patient safety, a systematic pharmaceutical analysis of chemotherapy prescriptions is performed in our institution. The aim of this study was to assess the impact of pharmaceutical interventions (PIs) on the safety of patient chemotherapy prescriptions. Methods: This prospective cross-sectional study was conducted in an 800-bed university hospital with oncology departments. All chemotherapy prescriptions were included and PIs were collected prospectively during one month. The clinical impact of PIs was scored by an expert panel of oncologists and pharmacists, using the Hatoum scale. Univariate and multivariate analysis were conducted to identify factors associated with a higher frequency of PIs. Results: Of 1346 prescriptions included, 129 required a PI (9.6% (95% CI: 8.1–11.4)). Most PIs were scored as having at least a significant impact for patient safety (69.8% (95% CI: 60.4–76.9)). The frequency of PIs was significantly associated with tumour site (p = 0.04) and weekday of prescription (p = 0.005). Multivariate analysis identified factors independently associated with PI performance, including pancreas and biliary tract cancers (odds ratio = 2.8 (95% CI: 1.4–5.3)), ovary cancers (odds ratio = 2.4 (95% CI: 1.2–4.8)) and head and neck cancers (odds ratio = 2.4 (95% CI: 1.1–5.1)) and the day 1 of the protocol with a cytotoxic agent (odds ratio = 3.7 (95% CI: 1.1–11.1)). Conclusions: Oncology pharmacists have a critical role in the safety of chemotherapy prescriptions. The coordination between healthcare professionals and access to patient data seem essential to improve the PIs' relevance and their clinical impact on patient safety.
- 28 January 2019
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 25 (5) , 1195-1203
Pharmaceutical interventions to improve safety of chemotherapy-treated cancer patients: A cross-sectional study
Purpose: Cancer chemotherapy is a high-risk process. To improve patient safety, a systematic pharmaceutical analysis of chemotherapy prescriptions is performed in our institution. The aim of this study was to assess the impact of pharmaceutical interventions (PIs) on the safety of patient chemotherapy prescriptions. Methods: This prospective cross-sectional study was conducted in an 800-bed university hospital with oncology departments. All chemotherapy prescriptions were included and PIs were collected prospectively during one month. The clinical impact of PIs was scored by an expert panel of oncologists and pharmacists, using the Hatoum scale. Univariate and multivariate analysis were conducted to identify factors associated with a higher frequency of PIs. Results: Of 1346 prescriptions included, 129 required a PI (9.6% (95% CI: 8.1–11.4)). Most PIs were scored as having at least a significant impact for patient safety (69.8% (95% CI: 60.4–76.9)). The frequency of PIs was significantly associated with tumour site (p = 0.04) and weekday of prescription (p = 0.005). Multivariate analysis identified factors independently associated with PI performance, including pancreas and biliary tract cancers (odds ratio = 2.8 (95% CI: 1.4–5.3)), ovary cancers (odds ratio = 2.4 (95% CI: 1.2–4.8)) and head and neck cancers (odds ratio = 2.4 (95% CI: 1.1–5.1)) and the day 1 of the protocol with a cytotoxic agent (odds ratio = 3.7 (95% CI: 1.1–11.1)). Conclusions: Oncology pharmacists have a critical role in the safety of chemotherapy prescriptions. The coordination between healthcare professionals and access to patient data seem essential to improve the PIs' relevance and their clinical impact on patient safety.
- 1 January 2018
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 111, 158-166
Rapid discrimination and quantification analysis of five antineoplastic drugs in aqueous solutions using Raman spectroscopy
- 1 January 2018
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 111, 158-166
Rapid discrimination and quantification analysis of five antineoplastic drugs in aqueous solutions using Raman spectroscopy
- 1 December 2015
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 58 (12) , 681-684
Enzymatic diagnosis of Fabry disease using a fluorometric assay on dried blood spots: An alternative methodology
- 1 December 2015
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 58 (12) , 681-684
Enzymatic diagnosis of Fabry disease using a fluorometric assay on dried blood spots: An alternative methodology
- 15 August 2004
- Published by Trans Tech Publications, Ltd. in Materials Science Forum
- Vol. 461-464, 175-182
A New Interpretation of the ''Breakaway'' Oxidation Behaviour Observed at High Temperature on 304 Stainless Steel
- 15 August 2004
- Published by Trans Tech Publications, Ltd. in Materials Science Forum
- Vol. 461-464, 175-182
A New Interpretation of the ''Breakaway'' Oxidation Behaviour Observed at High Temperature on 304 Stainless Steel
- 15 December 1999
- Published by EDP Sciences in The European Physical Journal Applied Physics
- Vol. 8 (3) , 233-240
Initial oxidation stage of yttrium-implanted pure iron at 700 °C by in situ high temperature X-ray diffraction
Oxidation study, at 700 °C and under controlled atmosphere (oxygen partial pressure: 0.04 Pa) for 24 h, of unimplanted or yttrium implanted pure iron specimens was carried out using in situ X-ray diffraction to observe the yttrium implantation effect. In situ X-ray diffraction analyses performed on unimplanted pure iron clearly show the formation of FeO (wustite) and Fe3O4 (magnetite) compounds at the beginning of the oxidation test whereas the formation of Fe2O3 (hematite) is only detected after 1h30 of oxidation. In situ X-ray diffraction analyses performed with the same experimental conditions on yttrium implanted pure iron show the presence of two Mayn yttrium-iron mixed oxides (i.e. FeYO3 and Fe2YO4) in combination with wustite, magnetite and hematite structures. The presence of the Fe2YO4 compound is important because several authors have reported its anticorrosion properties at high temperature. X-ray diffraction results also show that the formation of FeYO3 and Fe2YO4 is Maynly reinforced at the gas-oxide interface which suggests an outward yttrium diffusion through the oxide layer from implanted pure iron.
- 15 December 1999
- Published by EDP Sciences in The European Physical Journal Applied Physics
- Vol. 8 (3) , 233-240
Initial oxidation stage of yttrium-implanted pure iron at 700 °C by in situ high temperature X-ray diffraction
Oxidation study, at 700 °C and under controlled atmosphere (oxygen partial pressure: 0.04 Pa) for 24 h, of unimplanted or yttrium implanted pure iron specimens was carried out using in situ X-ray diffraction to observe the yttrium implantation effect. In situ X-ray diffraction analyses performed on unimplanted pure iron clearly show the formation of FeO (wustite) and Fe3O4 (magnetite) compounds at the beginning of the oxidation test whereas the formation of Fe2O3 (hematite) is only detected after 1h30 of oxidation. In situ X-ray diffraction analyses performed with the same experimental conditions on yttrium implanted pure iron show the presence of two Mayn yttrium-iron mixed oxides (i.e. FeYO3 and Fe2YO4) in combination with wustite, magnetite and hematite structures. The presence of the Fe2YO4 compound is important because several authors have reported its anticorrosion properties at high temperature. X-ray diffraction results also show that the formation of FeYO3 and Fe2YO4 is Maynly reinforced at the gas-oxide interface which suggests an outward yttrium diffusion through the oxide layer from implanted pure iron.